Pediatric Studies: Must Sponsors Meet Every Detail Of US FDA Request To Get Exclusivity?
Executive Summary
In suit against FDA, Amgen argues it provided sufficient data to obtain exclusivity for Sensipar but agency says too few patients were included in one study; court ruled against FDA in similar 2001 dispute.
You may also be interested in...
Pediatric Exclusivity: Court Backs US On When Studies 'Fairly Respond' To Requests
However, FDA must explain why denial of Sensipar's pediatric exclusivity was consistent with exclusivity award for J&J's Ortho Tri-Cyclen, US judge says. In swipe at plaintiff Amgen, court says pediatric study reports themselves guide exclusivity determinations, not the amount of effort a sponsor puts into those studies.
Merck Mevacor Exclusivity Will Run Until Dec. 15 Following FDA Reversal
FDA is granting Merck pediatric exclusivity for Mevacor (lovastatin) through Dec. 15 following consideration of clarified data submitted by the company.
Merck Mevacor Pediatric Exclusivity Gets July 3 Hearing; 5 Generics Stayed
The D.C. federal court is scheduled to hear arguments on Merck's Mevacor pediatric exclusivity application July 3.